Literature DB >> 23117335

Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen.

Yi-Xin Chen1, Xiao-Wen Chen, Chang-Gang Li, Li-Jie Yue, Hui-Rong Mai, Fei-Qiu Wen.   

Abstract

The exact mechanisms as to how platelets influence blood-borne metastasis remain poorly understood. Gangliosides, sialic acid-containing glycosphingolipids, are associated with tumor progression and metastasis in humans. Gangliosides isolated from tumor cells promote collagen-stimulated platelet aggregation and ATP secretion and enhance platelet adhesion to immobilized collagen. Gangliosides interact with a number of cell surface receptors including integrin receptors. In this study, we examined the effects of α2β1 integrin-mediated platelet adhesion to collagen and phosphotyrosine signaling of focal adhesion kinase, p125FAK (FAK). platelets pre-incubated with neuroblastoma tumor gangliosides (NBTGs) or their major component GD2 (disialoganglioside) were more adherent to immobilized collagen (OD570 0.43±0.12, 0.39±0.13) compared to platelets pre-incubated with MTB (0.14±0.06, p<0.001); the effect of NBTGs was blocked by F-17 anti-α2 antibody. Pre-incubation of platelets with NBTGs resulted in a marked increase in the phosphotyrosine content of p125FAK in the adherent platelets compared to the MTB-pre-incubated adherent platelets. F-17 anti-α2 antibody decreased protein tyrosine phosphorylation of NBTG-incubated platelets adherent to collagen. These results indicate that the tumor gangliosides enhance platelet adhesion to extracellular matrix collagen by upregulating integrin α2β1-mediated tyrosine phosphorylation of p125FAK, thereby providing insight into how this interaction may be involved in neuroblastoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117335     DOI: 10.3892/or.2012.2092

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

2.  Moving a Carbohydrate Mimetic Peptide into the clinic.

Authors:  Issam Makhoul; Laura Hutchins; Peter D Emanuel; Angela Pennisi; Eric Siegel; Fariba Jousheghany; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 3.  Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.

Authors:  Stefano Mastrangelo; Serena Rivetti; Silvia Triarico; Alberto Romano; Giorgio Attinà; Palma Maurizi; Antonio Ruggiero
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

Review 4.  CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.

Authors:  Yu-Huan Yang; Jia-Wei Liu; Chen Lu; Ji-Fu Wei
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

Review 5.  The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Authors:  Irena Horwacik
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

Review 6.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

7.  Expression of CXC chemokine receptor-4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy.

Authors:  Jing Sun; Chen Feng; Weiwei Liao; Hao Zhang; Suoqin Tang
Journal:  Oncol Lett       Date:  2014-04-03       Impact factor: 2.967

8.  Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells.

Authors:  Stanley Ly; Vivek Anand; Fouad El-Dana; Khoa Nguyen; Yiming Cai; Shirong Cai; Helen Piwnica-Worms; Debasish Tripathy; Aysegul A Sahin; Michael Andreeff; Venkata Lokesh Battula
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.